Martha Read, MD
Family Medicine · Decatur, ALNPI 1427465434
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Novo Nordisk at 24.9% of the total. Reporting peaked in 2021 at $965 and has fallen 86.2% since, to $133 in 2025.
Across 114 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$446
- AbbVie$265
- Amarin Pharma, Inc.$222
- Amgen$111
- AstraZeneca$96
- Daiichi Sankyo Inc.$57
- plus $595 from 19 others
What the payments were for
- Food & beverage$1,791100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $446 |
| AbbVie | 21 | $265 |
| Amarin Pharma, Inc. | 14 | $222 |
| Amgen | 6 | $111 |
| AstraZeneca | 6 | $96 |
| Daiichi Sankyo Inc. | 3 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $55 |
| Indivior Inc. | 2 | $53 |
| Astellas Pharma US Inc | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| GSK | 3 | $46 |
| Corcept Therapeutics | 2 | $42 |
| Merck | 3 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| Exact Sciences | 2 | $36 |
| Seqirus USA Inc | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Harmony Biosciences LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Optinose US, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
$1,791 in reported general payments places this provider in the 65th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 59 | $401 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $339 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $182 |
| Gabapentin | 11 | $162 |
| Atorvastatin Calcium | 18 | $140 |
| Levothyroxine Sodium | 16 | $135 |
| Losartan Potassium | 16 | $115 |
| Lisinopril | 17 | $111 |
| Metoprolol Succinate | 11 | $110 |
| Tizanidine Hcl | 14 | $102 |
| Doxycycline Hyclate | 14 | $100 |
| Amlodipine Besylate | 15 | $98 |
| Amoxicillin | 18 | $84 |
| Meloxicam | 14 | $53 |
| Levofloxacin | 11 | $49 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Decatur
- Edwin MatthewsDecatur$14K
- Lashelle BarmoreBirmingham$486K
- Regina BenjaminBayou la Batre$222K
- Jonathan ParkerMuscle Shoals$214K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Kelly HunterTuscaloosa$84K
- Daniel EnglertHuntsville$82K
- Joel LaughlinMobile$75K
- Ashleigh Butts-WilkersonMobile$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.